These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10843452)

  • 61. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
    Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
    Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine.
    Siracusano S; Niccolini B; Knez R; Tiberio A; Benedetti E; Bonin S; Ciciliato S; Pappagallo GL; Belgrano E; Stanta G
    Eur Urol; 2005 Mar; 47(3):327-33. PubMed ID: 15716196
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
    Pieras E; Palou J; Salvador J; Rosales A; Marcuello E; Villavicencio H
    Eur Urol; 2003 Aug; 44(2):222-5; discussoion 225. PubMed ID: 12875942
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The efficacy of urinary cytology in the detection of recurrent bladder tumours.
    Baltaci S; Süzer O; Ozer G; Bedük Y; Göğüş O
    Int Urol Nephrol; 1996; 28(5):649-53. PubMed ID: 9061424
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
    Ayed M; Ben Hassine L; Ben Slama R; Chelbi N; Ghozzi S; Drissi H; Jemni M; Chebil M
    Prog Urol; 1998 Apr; 8(2):206-10. PubMed ID: 9615929
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Postoperative bladder washing cytology after transurethral resection. Can it predict the recurrence of urothelial carcinoma?
    Iczkowski KA; Katz G; Cascione CJ
    Acta Cytol; 2004; 48(3):380-4. PubMed ID: 15192954
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
    Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
    J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
    Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
    J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [The role of telomerase activity in non-invasive diagnostics of bladder cancer].
    Glybochko PV; Alyaev JG; Potoldykova NV; Polyakovsky KA; Vinarov AZ; Glukhov AI; Gordeev SA
    Urologiia; 2016 Aug; (4):76-81. PubMed ID: 28247730
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Randomized study of single early instillation of (2"R)-4'-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma.
    Okamura K; Ono Y; Kinukawa T; Matsuura O; Yamada S; Ando T; Fukatsu T; Ohno Y; Ohshima S;
    Cancer; 2002 May; 94(9):2363-8. PubMed ID: 12015761
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up.
    Shinka T; Matsumoto M; Ogura H; Hirano A; Ohkawa T
    Int J Urol; 1997 Mar; 4(2):139-43. PubMed ID: 9179686
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan.
    Kojima T; Nishiyama H; Ozono S; Hinotsu S; Keino N; Yamaguchi A; Sakai H; Enomoto Y; Horie S; Fujimoto K; Matsuyama H; Okamura T; Kanimoto Y; Oya M; Nonomura N; Naito S; Akaza H
    Int J Clin Oncol; 2018 Dec; 23(6):1140-1147. PubMed ID: 29971622
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
    Bian W; Xu Z
    Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
    Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
    J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Serum uptake of doxorubicin intravesically administered soon after transurethral resection of bladder carcinoma].
    Nagakura K; Takao M; Odajima K; Ieda K; Fujioka T; Hayakawa M; Murai M; Nakamura H
    Hinyokika Kiyo; 1989 Sep; 35(9):1509-12. PubMed ID: 2816617
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy.
    Saika T; Tsushima T; Nasu Y; Arata R; Kaku H; Kusaka N; Kumon H
    Jpn J Clin Oncol; 2002 Nov; 32(11):461-5. PubMed ID: 12499418
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by postoperative urinary cytology.
    Badalament RA; Gay H; Cibas ES; Herr HW; Whitmore WF; Fair WR; Melamed MR
    J Urol; 1987 Oct; 138(4):763-5. PubMed ID: 3656528
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
    Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
    Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.